Timothée Klopfenstein

Author

Also Known As

A Riberi, D. Fournier, K Bouiller, L Hustache-Mathieu, L. Hustache-Mathieu, T. Klopfenstein, Timothee Klopfenstein, Timothée Klopfenstein, Vincent Gendrin

Publications

Citations

H-Index

Concepts

All Affiliations

L'Hôpital Nord Franche-Comté Centre Hospitalier Universitaire de Besançon Centre National de la Recherche Scientifique Faculté de médecine de Tunis Tunis El Manar University

About

Timothée Klopfenstein is an author at L'Hôpital Nord Franche-Comté specializing in medicine, covid-19, and covid-19 epidemiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	269
2	Public Health	4	4	248
3	Epidemiology	4	4	248
4	Hospital Medicine	1	1	15
5	International Health	1	1	208

Timothée Klopfenstein

Publications

682

Citations

H-Index

Page 1

	Year	Citations
Clinical features of COVID-19 and influenza: a comparative study on Nord Franche-Comte cluster Souheil Zayet, N’dri Juliette Kadiane-Oussou, Quentin Lepiller, Microbes and Infection Nord Franche-comte ClusterVirus EpidemiologyCovid-19 PandemicClinical EpidemiologyInternational Health	2020	208
New loss of smell and taste: Uncommon symptoms in COVID-19 patients on Nord Franche-Comte cluster, France Timothée Klopfenstein, H. Zahra, N’dri Juliette Kadiane-Oussou, International Journal of Infectious Diseases	2020	82
Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients Timothée Klopfenstein, Souheil Zayet, Anne Lohse, International Journal of Infectious Diseases	2020	76
Post-COVID-19 Syndrome: Nine Months after SARS-CoV-2 Infection in a Cohort of 354 Patients: Data from the First Wave of COVID-19 in Nord Franche-Comté Hospital, France Souheil Zayet, H. Zahra, Pierre‐Yves Royer, Microorganisms	2021	55
Leclercia adecarboxylata as Emerging Pathogen in Human Infections: Clinical Features and Antimicrobial Susceptibility Testing Souheil Zayet, Stephane Lang, Pauline Garnier, Pathogens	2021	46
Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration. Thierry Conrozier, Anne Lohse, Jean‐Charles Balblanc, PubMed	2020	42
Tularemia: A Case Series of Patients Diagnosed at the National Reference Center for Rickettsioses From 2008 to 2017 Anne Darmon-Curti, François Darmon, Sophie Edouard, Open Forum Infectious Diseases	2020	26
Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19) Anne Lohse, Timothée Klopfenstein, J.C. Balblanc, Microbes and Infection Acute Lung InjuryPredictive FactorsCovid-19 PandemicRespiratory InfectionInfectious Respiratory Disease	2020	21
COVEVOL: Natural Evolution at 6 Months of COVID-19 Louise Messin, Marc Puyraveau, Yousri Benabdallah, Viruses	2021	19
Outbreak of <i>Mycoplasma pneumoniae</i> pneumonia in hospitalized patients: Who is concerned? Nord Franche-Comté Hospital, France, 2023–2024 Souheil Zayet, Samantha Poloni, Julie Plantin, Epidemiology and Infection	2024	19

Page 1